Table 3.
Characteristic | Category | Severe Cases,a No. | %b | Risk Ratio | 95% CI | Adjusted RR | 95% CI |
---|---|---|---|---|---|---|---|
No. of comorbiditiesc | 0 | 139 | 42 | Ref | Ref | Ref | Ref |
1–2 | 243 | 51 | 1.2 | 1.0–1.4 | 1.2 | 1.0–1.4 | |
≥2 | 49 | 54 | 1.3 | 1.0–1.6 | 1.3 | 1.0–1.7 | |
Serotype category | PCV13 | 148 | 60 | 1.5 | 1.3–1.9 | 1.6 | 1.3–1.9 |
PPSV23nonPCV13 | 157 | 45 | 1.2 | 1.0–1.4 | 1.2 | 1.1–1.4 | |
Nonvaccine | 90 | 39 | Ref | Ref | Ref | Ref | |
Influenza vaccination | Yes | 86 | 41 | 0.81 | 0.68–0.97 | 0.77 | 0.64–0.93 |
No | 301 | 50 | Ref | Ref | Ref | Ref |
Abbreviations: CI, confidence interval; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; RR, risk ratio.
aSevere case = an IPD case with 1 of the following: ICU admission, shock or sepsis, or mechanical ventilation; risk = high-risk or at-risk case.
bProportion of cases that were severe.
cOne of the following comorbidities/conditions: heart disease, chronic lung disease, chronic liver disease, renal failure, chronic neurological disorder, diabetes mellitus, autoimmune disease, malnutrition, history of invasive pneumococcal disease, or pneumococcal pneumonia.